Short-term outcomes of albumin-bound paclitaxel (abraxane)-containing chemotherapy in patients with advanced gastric cancer: a report of 14 cases
- 131 Downloads
Albumin-bound paclitaxel (abraxane, ABX) has more favorable efficacy and less toxicity than conventional taxanes. However, the data of ABX in advanced gastric cancer (AGC) treatment is unavailable. The current study was designed to summarize our experience in treating AGC patients with ABX.
The clinical data of patients with AGC who had received at least one cycle of ABX-based chemotherapy in Sun Yat-sen University Cancer Center from January 10th 2010 to May 14th 2012 was retrospectively analyzed..
A total of 47 cycles of ABX-containing regimens, with a median of 3 cycles (range: 1–8 cycles), were administered to 14 patients. Five (35.7%) partial responses and 6 (42.9%) stable diseases were obtained, with a disease control rate (DCR) of 78.6%. The median progression free survival (PFS) and overall survival (OS) were 3.3 and 10.8 months, respectively. Interestingly, patients in the first-line setting achieved a DCR of 100% (8/8). Neutropenia and thrombocytopenia were the main grade 3/4 adverse events with an incidence of 50% in the whole group. However, only 25% patients (2/8) experienced grade 3 neutropenia when ABX in combination with fluoropyrimidines.
The activity of ABX-based regimens as first-line therapy for patients with AGC is remarkable, and the toxicity is mild when ABX combined with fluoropyrimidines. Further prospective clinical trials of ABX-based chemotherapy as first-line treatment for AGC are strongly anticipated.
Key wordsalbumin-bound paclitaxel (abraxane, ABX) gastric cancer efficacy toxicity chemotherapy
Unable to display preview. Download preview PDF.
- 6.John TA, Vogel SM, Tiruppathi C, et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol, 2003, 284: 187–196.Google Scholar
- 13.Hosein PJ, de Lima Lopes G Jr, Pastorini VH, et al. A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol, 2012, Feb 2.Google Scholar
- 19.Li P, Wang Q, Wang H, et al. Research progresses of albumin-bound paclitaxel in the treatment of non-small cell lung cancer. Chin J lung cancer (Chinese), 2010, 13: 748–752.Google Scholar
- 21.Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol, 2012, 30: 2055–2062.PubMedCrossRefGoogle Scholar
- 22.Coleman RL, Brady WE, McMeekin DS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol, 2011, 122: 111–115.PubMedCrossRefGoogle Scholar
- 23.Desai N, Trieu V, Yao R, et al. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albuminbound paclitaxel (ABI-007) vs taxol. Breast Cancer Res Treat, 2004, 88: S26–S27.Google Scholar
- 26.Desai N, Trieu V, Knauer D, et al. SPARC may be a predictive biomarker of response to nab-paclitaxel. Ejc Suppl, 2009, 7: 88.Google Scholar
- 35.Gradishar W, Krasnojon D, Cheporov S, et al. Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC). Ejc Supplements, 2008, 6: 172–172.Google Scholar